



SUPERWORKERSM

LIFE SCIENCES AND PHARMACEUTICAL

WHY YOUR PEOPLE, NOT YOUR AI IN CLINICAL
OPERATIONS, DECIDE WHAT PHARMA'S 2026
INSPECTION AND INNOVATION ARE WORTH.


YOUR WORLD

GxP and inspection readiness as practice evidence

Auditors no longer ask whether people were trained. **They ask whether people do it differently.** You have defined GxP practice per role across R&D, manufacturing and quality. You have signed off the SOPs. Now auditors want **evidence** that people **actually work that way.**

Your training completion dashboard lands silently. The inspection readiness sponsor's credibility is on the line. The evidence the auditor wants is already in your work.

It just is not being captured in the flow.



Multi-site cGMP consistency across manufacturing and quality

Pharma operates across sites. Each site has its own **quality leadership**, its own **pace**, its own **standard** of what cGMP looks like. The same SOP lands differently in each plant. Small variations add up to big recall risk. Big recall risk adds up to margin leak. Quality auditors see it. Regulators see it.

Nothing connects practice across sites. What connects them is not another training cycle. **It is one definition of good, applied locally.**

AI in discovery, clinical operations and post-market surveillance

Pharma has deployed AI across discovery labs, clinical trial operations and pharmacovigilance. The **tools** work **fast**. Your people adopt them at **different speeds**. Some skip steps. Some bypass the SOP. AI tools move faster than the governance can follow. Your Chief Medical Officer and Safety team are watching. Real-world evidence and clinical data quality depend on **your people actually following the protocol**. The gap between deployment and adoption is closeable. It does not need new technology.

EU AI Act high-risk workforce capability in scope

The EU AI Act now classifies **clinical trial and pharmacovigilance** work as **high-risk**. Workforce capability is formally in the regulation. Your AI vendor audits you on training. Your regulator audits you on proof. You have built the training programme.

Now you need evidence that people can **actually do the work the AI Act asks**. Your procurement and compliance team are waiting. The evidence you need is buildable. Most pharma is closer than they think.





WHERE SUPERWORKER PAYS FOR ITSELF

You do not need another platform. We sit on top of what you already have. We pay for ourselves by making the budget you have already approved go further. There are three places that is true.

We refocus your L&D and quality-training budget. Same envelope. Different mix. Less classroom and content licence. More activation in real R&D, manufacturing and quality work. The line item is the same. What you bill against it is different.


We replace the slowest part of your inspection-readiness activation. The pre-audit scrambles. The mock inspections. The training refreshes that do not change practice. Replaced with a four-week working rhythm at the bench, the line and the desk. This bills against quality and audit-readiness, not against L&D.

We unlock the value of the AI you have already deployed in discovery and clinical operations. Pharma now holds investment across discovery AI, clinical-operations AI and pharmacovigilance AI. Every percentage point of operator competence lift is real return the CFO can model. The systems are paid. We help your people actually use them inside SOP guardrails.

AI in discovery, clinical and post-market

Companion drives AI-tool adoption inside SOP guardrails. The Responsible AI Framework provides clinical-grade governance. The Reporting layer tracks operator competence.



HOW THIS WORKS FOR EACH ONE



EU AI Act high-risk

Builder defines workforce-capability requirements per the AI Act.

The Responsible AI Framework backs the procurement and audit story. The Reporting layer captures evidence.




GxP and inspection readiness

Builder defines GxP practice per role across R&D, manufacturing and quality. Companion captures application in the flow of work. The Reporting layer produces inspection-ready evidence as a by-product.

Multi-site cGMP

One Builder for cGMP standards across sites. Companion delivers site-specific coaching with a central baseline.





LET'S TALK

If any of these match your pharma business, your Quality, Medical or Compliance leader is already asking.

There is a gap between what you trained for and what you can prove. That gap decides the next inspection and AI investment return.

We work with Advisory Partners across South Africa, Australia, the Middle East and the United Kingdom. We will match you to the right partner for your region and your pharma business.

W&L HUMAN CAPITAL

EQUATE

TALEXUS

CAN!DO

FLOURISH COUNSELLING



DGE Recruit TALENT, NETWORK, VALUE

GENSAFE AI

blackslope



Book a meeting

We will show you what your inspection and AI governance walk into next.

SUPERWORKERSM

LET'S TALK

info@superworker.co
www.superworker.co



The framework is correct

The architecture is correct

The pacing is the issue



SUPERWORKERSM

CONFIDENTIALITY NOTICE

All rights, including copyright, in the content of this proposal are owned or controlled by SUPERWORKER® PTY LTD. The contents of these pages are provided for the sole purpose of evaluating Sibanye Stillwater's commercial offer and approach. No part of this proposal may be reproduced, distributed, or used for any other purpose without the explicit written consent of SUPERWORKER®. In accessing this document, you agree that you may only download the content for personal, non-commercial use in relation to its evaluation. Confidentiality information means all proprietary and confidential of the Parties and those of their customers, clients or suppliers whether commercial, financial, technical or otherwise (whether oral, in writing, machine readable or in any other form) and material (whether electronically recorded, in writing or otherwise), which by its very nature should obviously be treated as secret and confidential and which the Parties desire to protect against unrestricted disclosure or competitive use or which is designated as such, including without limitation.

COPYRIGHT NOTICE ©2026 SUPERWORKER PTY LTD

Information relating directly or indirectly to each Party's business, not limited to details of trade secrets, know-how, strategies, ideas, operations, compliance information, processes, methodologies and practises; and Information relating directly or indirectly to plans, intentions, know-how, market opportunities and business affairs or those of its suppliers, customers (including potential customers) and clients; and Works of authorship, products and materials written and prepared by the Parties in relation to this agreement, including but not limited to computer programmes, data, diagrams, charts, reports, specifications, sketches, inventions and working papers of similar materials of whatever nature or on whatever media relating thereto; and Information resulting directly or indirectly from the discussion or negotiations relating to this agreement and all copies, notes, records and all related information based on or arising from any disclosures from this agreement; and the terms of any agreement reached by the Parties or proposed by either Party (whether agreed or not) in connection